Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Senate Panel Clears $275 Million In Immediate Extra Funding For FDA

This article was originally published in The Gray Sheet

Executive Summary

A supplemental appropriations/war funding measure containing $275 million for FDA cleared the Senate Appropriations Committee May 15 but faces a tougher go in both the House and the White House

You may also be interested in...



A Matter Of $275 Million: Congress And White House Tussle Over FDA Funds

The Bush Administration tried to get ahead of Congress' relentless criticism that it is under-funding FDA last week by adding $275 million for the agency to its fiscal year 2009 budget request. Critics on Capitol Hill were not impressed

A Matter Of $275 Million: Congress And White House Tussle Over FDA Funds

The Bush Administration tried to get ahead of Congress' relentless criticism that it is under-funding FDA last week by adding $275 million for the agency to its fiscal year 2009 budget request. Critics on Capitol Hill were not impressed

Senate votes CDRH $35.5 million in supplemental appropriations

FDA's device center would receive $35.5 million in additional appropriations for fiscal 2008 under a broad defense and domestic funding bill passed by the Senate May 22, according to Hill staffers. FDA would receive $275 million in additional funds overall. The increase will still have to be reconciled with a May 15 House supplemental funding package with no extra funds for FDA ("1The Gray Sheet" May 19, 2008, p. 3)

Latest Headlines
See All
UsernamePublicRestriction

Register

MT026136

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel